Dr. Billings is a board-certified internist and clinical geneticist with more than 30 years of experience in genomics and molecular medicine. He is the author of nearly 200 publications on genomic medicine and has held academic and research appointments at Harvard University, UC San Francisco, Stanford University, and UC Berkeley. Dr. Billings is currently the Chief Medical Officer at Natera. He previously held the position of Chief Medical Officer at Life Technologies, Inc., and consulting CMO of the Genetic Sciences Division of Thermo Fisher Scientific. He previously was SVP and Senior Physician at Laboratory Corporation of America Holdings. He has served on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the HHS Secretary’s Advisory Committee on Genomics, Health and Society. His work formed the basis of the Genetic Information Nondiscrimination Act of 2008 (GINA).
Dr. Martinez is the executive Vice Chair of Medicine at Weill Cornell Medical College. He has been listed in “Best Doctors of America” every year since 2002. Dr. Martinez is a premiere translational researcher in chronic lung disease, and is nationally and internationally recognized for his grant-funded seminal studies in the phenotypic and functional classification, and clinical interventions in COPD and interstitial lung disease. He has authored 326 peer-reviewed manuscripts, 36 review articles in addition to 32 book chapters, and has mentored numerous trainees, with many of his mentees establishing successful independent research programs.
Dr. Martinez received both his BSc and M.D. at the University of Florida and completed his Internal Medicine residency at Beth Israel Hospital/Harvard Medical School in 1986. He then held a Pulmonary and Critical Care Medicine Fellowship at Boston University prior to joining University of Michigan Medical Center as Assistant Professor of Medicine in 1991, where he rose to the rank of Professor of Medicine in 2002 and served in a number of medical leadership positions. He received an MS in Biostatistics and Clinical Study Design Biostatistics and Clinical Study Design from the University of Michigan, School of Public Health in 2001. He was appointed to his current position in 2014.
Professor Stockley is currently Professor of Medicine at the University Hospital Birmingham and director of the Lung Immunobiochemical Research Group. He has a longstanding interest in COPD phenotypes with particular reference to airway inflammation, proteinases and anti-proteinases, and especially the role of the neutrophil, bacteria and exacerbations and lectures widely on these aspects. He acts as advisor to many Pharmaceutical companies on the design and delivery of Phase 2&3 clinical trials and has been PI for several large multinational COPD trials. Professor Stockley established and organises the UK alpha-1-antitrypsin deficiency database and leads the UK National Institute of Health Research Network for rare diseases (Alpha-1-Antitrypsin Deficiency). He established the International Registry for the deficiency (AIR) which currently includes over 5000 patients and has acted as chair for many years. He has been co-ordinator for multi-centre trials of augmentation therapy and alveolar regeneration in these patients and currently leads an ERS Task Force developing an updated statement on management of the condition.
He has been a member of the GOLD scientific committee since 2010 and member of the Executive committee and Board of directors. He is currently involved in the 2016 update. He has published more than 400 peer-reviewed papers, reviews, and chapters, edited 7 books, supervised 35 higher degree theses in clinical and basic science and been a member of the editorial board of more than 15 journals, including Chest, Thorax, European Respiratory Journal, Respiratory Research and Journal of COPD .